SCHEMBL440933

SCHEMBL440933

[C]1CCn2ccnc2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2306551 0.78
SCHEMBL712267 0.67
SCHEMBL439864 0.67
SCHEMBL238844 0.65
SCHEMBL23567310 0.64
SCHEMBL112245 0.64
SCHEMBL12604725 0.64 PDPK1 (0.45)
Hydrochloric Acid SCHEMBL5598004 0.64 PDPK1 (0.45)
Ammonia Solution, Strong SCHEMBL29261101 0.64 PDPK1 (0.45)
SCHEMBL23335459 0.64 PDPK1 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11925629-B2 Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer ASANA BIOSCIENCES, LLC (US) 2024-03-12 US disclosed
EP-3307727-B1 HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER ASANA BIOSCIENCES LLC (US) 2023-10-04 EP disclosed
US-20230051842-A1 HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER ASANA BIOSCIENCES, LLC 2023-02-16 US disclosed
US-20230027072-A1 IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 ASANA BIOSCIENCES, LLC 2023-01-26 US disclosed
WO-2021086726-A1 IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 Asan BioSciences, LLC (US) 2021-05-06 WO disclosed
US-10751332-B2 Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer ASANA BIOSCIENCES, LLC (US) 2020-08-25 US disclosed
US-20200179356-A1 HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER ASANA BIOSCIENCES, LLC 2020-06-11 US disclosed
US-10471051-B2 Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer ASANA BIOSCIENCES, LLC (US) 2019-11-12 US disclosed
US-10344031-B2 Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2019-07-09 US disclosed
US-20180354951-A1 Substituted Pyrazolo[1,5-a] Pyridine As Tropomyosin Receptor Kinase (trk) Inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2018-12-13 US disclosed
US-20150005280-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2015-01-01 US disclosed
US-20140371217-A1 SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2014-12-18 US disclosed
EP-2791139-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS Dr. Reddy's Laboratories Ltd. (IN) 2014-10-22 EP disclosed
EP-2791138-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS Dr. Reddy's Laboratories Ltd. (IN) 2014-10-22 EP disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 US disclosed
WO-2013088257-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2013-06-20 WO disclosed
WO-2013088256-A1 SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2013-06-20 WO disclosed
EP-2601192-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2013-06-12 EP disclosed
US-20120065196-A1 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-15 US disclosed
WO-2012018909-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-09 WO disclosed